No annual revenue total was found in TRANSCODE THERAPEUTICS, INC.'s SEC filings.
Transcode Therapeutics, Inc. (RNAZ) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$19.5 million.
Revenue
—
Net income (TTM)
$-42.83M
-74.1% vs year-ago TTM
Operating cash flow (TTM)
$-22.61M
-57.5% vs year-ago TTM
Free cash flow
$-19.52M
-46.2% vs prior year
EPS (TTM)
$-51.21
+46.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
916,968
+0.0% vs prior year
Net cash
$5.77M
FY 2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNAZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1829635
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$28.0M | -$15.7M | -$19.4M | -$18.6M | -$6.2M |
| Net income | -$34.7M | -$16.8M | -$18.5M | -$17.6M | -$6.8M |
| Diluted EPS | -$52.59 | -$1,336.63 | -$3,419.01 | -$1,082.79 | -$0.81 |
| Operating cash flow | -$19.5M | -$13.3M | -$18.1M | -$15.8M | -$5.3M |
| Free cash flow | -$19.5M | -$13.4M | -$18.1M | -$15.9M | -$5.5M |
| Total assets | $162.4M | $7.3M | $5.2M | $7.6M | $22.9M |
| Total liabilities | $10.5M | $9.3M | $3.5M | $4.3M | $2.5M |
| Stockholders' equity | $10.3M | -$2.0M | $1.6M | $3.2M | $20.4M |
| Cash and investments | $17.8M | $5.8M | $2.8M | $5.0M | $20.8M |
| Total debt | — | $38,291 | $450,571 | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 11, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Aug 3, 2026 | Aug 3, 2026 |
All 324 Transcode Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.